Format

Send to

Choose Destination
Medicine (Baltimore). 2019 Jun;98(26):e15947. doi: 10.1097/MD.0000000000015947.

Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab: ACT-AXIS study.

Author information

1
Rheumatology Department, Hospital Sant Joan Despí Moises Broggi.
2
Department of Rheumatology, Hospital Vall d'Hebrón.
3
Department of Rheumatology, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona.
4
Department of Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia.
5
Department of Rheumatology, Hospital General de l'Hospitalet, L'Hospitalet de Llobregat.
6
Department of Rheumatology, Complejo Hospitalario Cristal Piñor, Ourense.
7
Complejo Hospitalario Arquitecto Marcide-Profesor Novoa Santos, A Coruña.
8
Department of Rheumatology, Xarxa Sanitaria i Social de Santa Tecla, Tarragona.
9
Department of Rheumatology, Hospital General Universitario Santa María del Rosell, Cartagena, Murcia.
10
Department of Rheumatology, Corporació Sanitària Parc Taulí, Barcelona.
11
Department of Rheumatology, Hospital da Costa Burela, Burela, Lugo.
12
Department of Rheumatology, Hospital Rafael Méndez, Lorca, Murcia.
13
Department of Rheumatology, Hospital Universitari Sant Joan de Reus, Tarragona.
14
Department of Rheumatology, Clínica Girona, Girona.
15
Department of Rheumatology, Hospital de Mollet, Mollet del Valles, Barcelona.
16
Hospital Xeral Cies, Vigo, Pontevedra.
17
Medical Department, Roche Farma S.A., Spain.

Abstract

To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ.A 24-week, multicenter, prospective, observational study in patients with moderate to severe RA receiving TCZ after failure or intolerance to disease-modifying antirheumatic drugs or tumor necrosis factor-alpha was conducted.Of the 122 patients included, 85 were evaluable for effectiveness (85% female, 51.9 ± 12.5 years, disease duration 8.7 ± 7.4 years). Mean change in C-reactive protein level from baseline to week 12 was -11.2 ± 4.0 (P < .001). Mean Disease Activity Index score (DAS28) decreased from 5.5 ± 1.0 at baseline to 2.7 ± 1.3 (P < .001) at week 24. Mean change in Functional Assessment of Chronic Illness Therapy score was -5.4 ± 11.2 points at week 24. Multiple regression analysis showed that the improvement in DAS28, sleep, and depression explained 56% and 47% of fatigue variance at week 12 and 24, respectively.Tocilizumab is effective in reducing disease activity and results in a clinically significant improvement in fatigue, pain, swollen joint count, morning stiffness, sleepiness, depression, and DAS28; the last 3 were specifically identified as factors explaining fatigue variance with the use of TCZ in RA patients.

PMID:
31261500
PMCID:
PMC6617279
DOI:
10.1097/MD.0000000000015947
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center